Search results
Earnings call: Editas Medicine outlines strategic pillars for 2024 By Investing.com
Investing.com· 7 days agoEditas Medicine (NASDAQ:EDIT) has reported significant strides in its first quarter of 2024,...
Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down
Zacks via Yahoo Finance· 7 days agoEditas Medicine, Inc. Price, Consensus and EPS Surprise Editas Medicine, Inc. price...
Director Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc (EDIT)
GuruFocus.com via Yahoo Finance· 1 day agoOn May 13, 2024, Jessica Hopfield, Director at Editas Medicine Inc (NASDAQ:EDIT), purchased 45,000...
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
Motley Fool via Yahoo Finance· 7 days agoIn the wake of Editas' latest earnings release, she shaved $1 off her price target on the company to...
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest...
Simply Wall St. via Yahoo Finance· 4 days agoThere's been a definite change in sentiment in this update, with the analysts administering a...
CRISPR can treat common form of inherited blindness, early data hint
Live Science via Yahoo News· 20 hours agoA photo shows two male doctors in surgery garb as one preps a long needle for a procedure. A patient...
Gene Editing Breakthrough: CRISPR Improves Vision in Clinical Trial
SciTechDaily· 3 days agoMass Eye and Ear researchers say their findings support continued research and clinical trials of...
How Editas 'dragged' Linda Burkly over as CSO after 37 years at Biogen
FierceBiotech· 6 days agoLinda Burkly, Ph.D., was 37 years into a career at Biogen when Editas Medicines CEO Gilmore...
CRISPR gene editing may help treat rare eye disorder, improve vision
Medical News Today· 7 days ago“This [is] a blinding disease with no treatments,” Mark Pennesi, MD, PhD, professor of ophthalmology...